{"prompt": "['Dermatological irAEs', 'Grade of Rash', '(NCI-CTCAE v4)', 'Initial Management', 'Follow-up Management', 'Grade 1 to 2', 'Continue avelumab therapy', 'If persists > 1 to 2 weeks or recurs:', 'Covering Y 30% body surface', 'Symptomatic therapy (for', 'Withhold avelumab therapy', 'area', 'example, antihistamines,', 'Consider skin biopsy', 'topical steroids)', 'Consider 0.5-1.0 mg/kg/day', 'prednisone or equivalent. Once', 'improving, taper steroids over at', 'least 1 month, consider', 'prophylactic antibiotics for', 'opportunistic infections, and', 'resume avelumab therapy following', 'steroids taper.', 'If worsens:', 'Treat as Grade 3 to 4.', 'Grade 3 to 4', 'Withhold avelumab for', 'If improves to Grade V 1:', 'Grade 3: Covering > 30%', 'Grade 3.', 'Taper steroids over at least 1', 'body surface area;', 'Permanently discontinue for', 'month; resume avelumab therapy', 'Grade 4: Life threatening', 'Grade 4 or recurrent Grade 3.', 'following steroids taper (for initial', 'consequences', 'Consider skin biopsy', 'Grade 3).', 'Dermatology consult', '1.0 to 2.0 mg/kg/day', 'prednisone or equivalent', 'Add prophylactic antibiotics', 'for opportunistic infections', 'CONFRONT Study v. 1.1 del 07/05/2018 - Study Protocol', '30']['Pulmonary irAEs', 'Grade of Pneumonitis', '(NCI-CTCAE v4)', 'Initial Management', 'Follow-up Management', 'Grade 1', 'Consider withholding', 'Re-assess at least every 3 weeks', 'Radiographic changes only', 'avelumab therapy', 'If worsens:', 'Monitor for symptoms every', 'Treat as Grade 2 or Grade 3 to 4.', '2 to 3 days', 'Consider Pulmonary and', 'Infectious Disease consults', 'Grade 2', 'Withhold avelumab therapy', 'Re-assess every 1 to 3 days', 'Mild to moderate new', 'Pulmonary and Infectious', 'If improves:', 'symptoms', 'Disease consults', 'When symptoms return to Grade <', 'Monitor symptoms daily;', '1, taper steroids over at least 1', 'consider hospitalization', 'month, and then resume avelumab', '1.0 to 2.0 mg/kg/day', 'therapy following steroids taper', 'prednisone or equivalent', 'If not improving after 2 weeks or', 'Add prophylactic antibiotics', 'worsening:', 'for opportunistic infections', 'Treat as Grade 3 to 4.', 'Consider bronchoscopy, lung', 'biopsy', 'Grade 3 to 4', 'Permanently discontinue', 'If improves to Grade V 1:', 'Grade 3: Severe new', 'avelumab therapy.', 'Taper steroids over at least 1 month', 'symptoms; New/worsening', 'Hospitalize.', 'If not improving after 48 hours or', 'hypoxia;', 'Pulmonary and Infectious', 'worsening:', 'Grade 4: Life-threatening', 'Disease consults.', 'Add additional immunosuppression', '1.0 to 2.0 mg/kg/day', '(for example, infliximab,', 'prednisone or equivalent', 'cyclophosphamide, IV', 'Add prophylactic antibiotics', 'immunoglobulin, or mycophenolate', 'for opportunistic infections', 'mofetil)', 'Consider bronchoscopy, lung', 'biopsy', 'CONFRONT Study v. 1.1 del 07/05/2018 - Study Protocol', '31']['Hepatic irAEs', 'Grade of Liver Test Elevation', '(NCI-CTCAE v4)', 'Initial Management', 'Follow-up Management', 'Grade 1', 'Continue avelumab therapy', 'Continue liver function monitoring', 'Grade 1 AST or ALT > ULN', 'If worsens:', 'to 3.0 x ULN and/or Total', 'Treat as Grade 2 or 3 to 4.', 'bilirubin > ULN to 1.5 X ULN', 'Grade 2', 'Withhold avelumab therapy', 'If returns to Grade V 1:', 'AST or ALT > 3.0 to5 x', 'Increase frequency of', 'Resume routine monitoring; resume', 'ULN and/or total bilirubin >', 'monitoring to every 3 days.', 'avelumab therapy.', '1.5 to VI 3 x ULN', 'If elevation persists > 5 to 7 days or', 'worsens:', 'Treat as Grade 3 to 4.', 'Grade 3 to 4', 'Permanently discontinue', 'If returns to Grade < 1:', 'AST or ALT > 5 x ULN', 'avelumab therapy', 'Taper steroids over at least 1 month', 'and/or total bilirubin > 3 X', 'Increase frequency of', 'If does not improve in > 3 to 5', 'ULN', 'monitoring to every 1 to 2 days', 'days, worsens or rebounds:', '1.0 to 2.0 mg/kg/day', 'Add mycophenolate mofetil 1 gram', 'prednisone or equivalent', '(g) twice daily', 'Add prophylactic antibiotics', 'If no response within an additional', 'for opportunistic infections', '3 to 5 days, consider other', 'Consult gastroenterologist/', 'immunosuppressants per local', 'hepatologist', 'guidelines.', 'Consider obtaining MRI/CT', 'scan of liver and liver biopsy if', 'clinically warranted', 'Renal irAEs', 'Grade of Creatinine Increased', '(NCI-CTCAE v4)', 'Initial Management', 'Follow-up Management', 'Grade 1', 'Continue avelumab therapy', 'Continue renal function', 'CONFRONT Study v. 1.1 del 07/05/2018 - Study Protocol', '32']\n\n###\n\n", "completion": "END"}